Evotec licenses Ncardia’s disease modeling patents

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: License, Patent, Stem cell

Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.

Ncardia – which was established in September 2017 following the merger of Pluriomics and Axiogenesis – provides standardized, validated induced pluripotent stem cell (iPSC)​ assays for safety, phenotypic screening, and disease modeling.

The company’s product portfolio encompasses a panel of hiPSC derived cryopreserved cardiomyocytes and neurons. It also delivers the CardioPlate product line of quality controlled ready to use assay plates.

The agreement – financial terms of which were not disclosed – is the second for Ncardia in the past two months. In October, the company announced a license agreement with Roche, Ncardia’s first pharmaceutical partner.

As part of the agreement, Roche has a worldwide license to Ncardia’s disease modeling patents to further discovery and development of novel drug candidates.

The company also completed a €10.5m ($12.42) Series B financing round in November.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars